Sanofi-aventis delivers a solid performance in third quarter 2009
- Details
- Category: Sanofi
In the third quarter of 2009, sanofi-aventis generated net sales of €7,400 million, up 8.0% on a reported basis. Exchange rate movements had a favorable effect of 2.0 percentage points, with the appreciation of the U.S. dollar (and to a lesser extent the yen) against the euro more than offsetting the unfavorable effects of some other currencies.
Lilly CEO Lechleiter Calls for Repair of the 'Engine of Biopharma Innovation'
- Details
- Category: Eli Lilly and Company
In a speech to the City Club of San Diego, John C. Lechleiter, Ph.D., chairman and chief executive officer of Eli Lilly and Company (NYSE: LLY), said that the engine of biopharmaceutical innovation is "broken." He offered a vision for biopharmaceutical companies to "reinvent innovation" to make the most of today's wealth of scientific knowledge to benefit patients and address unmet medical needs.
Novartis on track to deliver Influenza A (H1N1) vaccine for the US
- Details
- Category: Novartis
Novartis has shipped over 7.5 million doses of Influenza A(H1N1)[1] vaccine ready to use and expects 25 to 30 million doses of unadjuvanted vaccine to become available in pre-filled syringes and multi-dose vials by the end of November. Smaller changes in delivery timelines and volumes can result out of the variability of the underlying biological production process. The deliveries are in line with commitments made to the US Department of Health and Human Services (HHS).
Novel agent for treatment of Parkinson's disease - Lu 02-750
- Details
- Category: Lundbeck
H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu 02-750 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans. The placebo-controlled study is expected to enrol around 100 healthy individuals.
Novo Nordisk increased operating profit by 30% in the first nine months of 2009
- Details
- Category: Novo Nordisk
Sales increased by 15% in Danish kroner and by 11% in local currencies:
-
Sales of modern insulins increased by 28% (24% in local currencies).
Sales of NovoSeven® increased by 15% (11% in local currencies).
Sales of Norditropin® increased by 15% (9% in local currencies).
Sales in North America increased by 29% (17% in local currencies).
Sales in International Operations increased by 18% (16% in local currencies).
AstraZeneca PLC Third Quarter & Nine Months Results 2009
- Details
- Category: AstraZeneca
Revenue in the third quarter increased by 10 percent at CER, but was up 5 percent on an actual basis as a result of the negative impact of exchange rate movements. Revenue benefited from strong growth of the Toprol-XL franchise in the US as a result of the market withdrawal by two generic competitors and from revenues from US government orders for vaccine for Novel Influenza A (H1N1); adjusting for these factors, global revenue increased by 5 percent.
Abbott completes acquisition acquisition of privately held eye care company Visiogen
- Details
- Category: Abbott
Abbott (NYSE: ABT) has completed its acquisition of privately held eye care company Visiogen, expanding the company's vision care business with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients.
More Pharma News ...
- Forest Laboratories, Inc. and Gedeon Richter Announce Results from a Phase IIb Study of Cariprazine
- Pandemrix data in an elderly population
- Boehringer Ingelheim Animal Health closes deal to acquire Animal Health Business from Pfizer
- Novartis delivers strong new product momentum and operational performance
- Merck Revenues Increase by 2.7% to € 1.9 Billion
- FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity
- Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement